We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.
We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.
We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.
We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.
We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.
We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.
We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.
We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.
We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.
We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.
We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.
We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.
We are evaluating the long-term safety of treatments for pulmonary hypertension in participants who have previously received these interventions. This study aims to ensure ongoing safety for those already involved in related research.
We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.
We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.
We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.
We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.
We are studying whether adding ARIKAYCE to standard treatment helps people with Mycobacterium xenopi lung infections clear the infection more effectively. The trial will measure how quickly and effectively the treatment works compared to standard care alone.
We are investigating if treatment choices based on biomarker signatures can improve survival and quality of life for patients with metastatic prostate cancer. This study compares these personalized approaches to standard care.
We are comparing the effects of continuing versus stopping immunosuppression in patients with late renal graft failure. This study aims to see how these approaches impact health outcomes over two years.